MedTrace Logo

Teclistamab-Daratumumab in AL Amyloidosis

NCT07110844 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2025-11-19

No results posted yet for this study

Summary

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.

The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.

Conditions

  • Amyloid Light-chain Amyloidosis

Interventions

DRUG

Teclistamab

Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.

DRUG

Daratumumab and Hyaluronidase-fihj

Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.

Sponsors & Collaborators

  • Janssen Pharmaceuticals

    collaborator INDUSTRY

  • Suzanne Lentzsch, MD

    lead OTHER

Principal Investigators

  • Suzanne Lentzsch, MD, PhD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-07
Primary Completion
2031-10-31
Completion
2033-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07110844 on ClinicalTrials.gov